Angion
Uniondale · Founded 1998
About Angion
Angion Biomedica is a clinical-stage organ restoration biopharmaceutical company focused on renal disease. Its investigational drug BB3 is entering phase 3 for delayed graft function following kidney transplant and phase 2 for acute kidney injury following open-heart surgery using cardiopulmonary bypass.
Company Facts
- Founded: 1998
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $84.3M
- Funding stage: M&A
- Last round: Post-IPO Equity (Feb 2021)
- Ticker: nasdaq:ANGN
- Website: angion.com
- Phone: 5168691359
Industries & Categories
Biopharma, Biotechnology, Medical
Social Profiles
Canonical: https://fsome.com/organization/angion-124936 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.